Ceibo Health Consulting’s Post

When was the last time you read a whitepaper? Here's one we worked on for Cavenagh Health to add to your reading list 👇 For many companies, whitepapers are a valuable resource – allowing them to take an in-depth exploration into a specific topic. Specialist Life Science recruitment partner, Cavenagh Health, recently released their latest whitepaper ‘Beyond antibiotics: The reckoning of Antimicrobial Resistance - A new biological frontier’ in collaboration with INCATEurope and a consortium of esteemed industry experts, to spotlight the urgent collective effort needed against AMR. To help them call scientists, investors, entrepreneurs, and patients to action, our team designed and supported the development of their 70-page whitepaper. As a result, Cavenagh raised awareness of the scientific, commercial and regulatory challenges in combating AMR for over 1400 people across the biotech, life science and investor communities globally. Have a read of Cavenagh’s whitepaper:  https://lnkd.in/eCfNmhEj Have a topic you’d like to explore in more depth? Contact us to learn how we can support you: https://lnkd.in/em5rjyCE #SomXDesign #AMR #LifeSciences #Healthtech

🌍 Breaking Global Pharma & Health Updates! 🌍 🚨 In my latest YouTube video, I dive into the Top International Pharma & Health News for 14th December 2024. Stay ahead of the curve with these must-know updates from across the globe! 🌐 🎥 Watch the full video here: https://lnkd.in/gCwfAQvm 💬 Let’s connect: Which of these global trends do you think will shape the future of healthcare? Share your thoughts in the comments below! #GlobalHealth #PharmaNews #Healthcare #PharmaInnovation #HealthTech

New from PORTAL in JAMA Health Forum: Benjamin Rome, Anushka B., and Aaron S. Kesselheim, M.D., J.D., M.P.H. examine the use of and spending on Humira (adalimumab) following the introduction of the first adalimumab biosimilar to the US market in 2023. They find biosimilars made up <2% of adalimumab use in 2023 and that while net spending on Humira dropped by >40%, the biologic's list price increased by 8%. This indicates that Humira's manufacturer, AbbVie, likely offered sizeable rebates to health plans and PBMs to retain Humira's dominance on formularies. Full paper: https://lnkd.in/eixihVYp

The latest BHI E-Newsletter is live with stories including: 🏭 MilliporeSigma Opens €290 Million Biosafety Testing Facility: A new facility in Rockville will enhance biosafety testing services amid growing global demand. 💰 SK bioscience Acquires Stake in Fina BioSolutions LLC: A $3 million investment makes SK bioscience the first strategic investor in the Rockville-based biotech firm. 🩸 AMPEL BioSolutions Launches Heart Disease Predictive Test: A new blood test aims to predict heart disease and support therapeutic interventions. 🏥 Children's National Hospital Ranks Among Best: The facility has earned a spot on the U.S. News & World Report Honor Roll for the eighth consecutive year. 💵 TEDCO Invests $100K in Mental Health Solutions Company: A recent investment in Person Care supports digital health initiatives for complex mental health conditions. 🌍 PQE Group Recognized for Business Excellence: The company has won the Best Managed Companies Award for the fourth consecutive year in Italy. 🤝 Children’s National-led Consortium Collaborates with European Partners: A new partnership aims to accelerate pediatric medical device innovation addressing rare diseases. 📈 J.P. Morgan's Q3 2024 Life Sciences VC Update: The report highlights strong healthcare investments, rising deal activity, and a revival in the exit market for VC-backed companies. https://lnkd.in/e88jD_Yn

Real-world evidence (RWE) is becoming increasingly important in a changing clinical studies world.   With the rise of digital health tools and robust health registries, RWE is playing an important role in drug efficacy, safety, and reimbursement decisions.   At Abacus Medicine Pharma Services, we utilise real-world insights to support the commercialisation of our partners' rare disease assets in European markets.   Interested in learning how RWE is shaping the future of healthcare and how we can help demonstrate the value of your rare disease asset?    Click here to read the full article: https://lnkd.in/dUxw8ZAs

Despite great patient need and a plethora of growth opportunities, the biopharma market in low- and middle-income countries remains largely untapped.   As health-related suffering is expected to rise three times faster in these countries than in high-income ones, it is urgent that biopharma leaders work to increase the accessibility of crucial medicines.   A new BCG article, “How Biopharma Can Make a Difference in Health Equity,” co-authored by my colleagues Johanna Benesty, Suchita Shah, and Regina Osih MD, MPH, provides a roadmap for biopharma companies to impactfully contribute to global health equity: https://lnkd.in/euFd_FcZ

Despite great patient need and a plethora of growth opportunities, the biopharma market in low- and middle-income countries remains largely untapped.   As health-related suffering is expected to rise three times faster in these countries than in high-income ones, it is urgent that biopharma leaders work to increase the accessibility of crucial medicines.   A new BCG article, “How Biopharma Can Make a Difference in Health Equity,” co-authored by my colleagues Johanna Benesty, Suchita Shah, and Regina Osih MD, MPH, provides a roadmap for biopharma companies to impactfully contribute to global health equity: https://lnkd.in/e9WS7xXX

Yet again, access to medicine is blocked by profit-seeking, reports health watchdog Public Citizen. Companies Cepheid and Danaher Corporation are charging $20 per mpox test for low- to middle-income countries. Estimated production costs show each test could be sold at a profit for $5. Public Citizen Access to Medicines Director Peter Maybarduk says “Cepheid and Danaher’s test prices totally disregard patient care. African countries are struggling to manage multiple mpox outbreaks while Cepheid and Danaher price gouge. Cepheid and Danaher must lower the price of GeneXpert tests and prioritize supply to the DRC and other African countries now. It’s time for $5.” Read more 👇🏼 https://bit.ly/3ZPenwf

Over the last three years, the #biopharma world has experienced a surge, with a sixfold increase in approved #ConnectedHealth products, now comprising 19% of the market. Key insights to know: *The number of organizations developing or testing such products has skyrocketed from 13% to 35%. *Motivations are high, driven by the desire to enhance #PatientSupport (85%) and gain deeper clinical insights (83%). Stay abreast of all the current trends in connected health. Download our report now: https://lnkd.in/g24u_aPr #HLTH #HLTHEurope #GetTheFutureYouWant #ConnectedHealth #LifeScience #ConnectedWorld #ConnectedProdcuts #ConnectedServices Jeff Hebert I Charlotte Pierron-Perlès I Christian Michalak I Christian Ramcke I Bora Ger I Chiara Diana I Caroline Gudmundsson